Fludarabine
Immunodeficiency Syndrome
Roswell Park Cancer InstituteSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Immunodeficiency Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Busulphan University of California, San Francisco | Phase 2 | BB |
Evomela Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | BB |
Thiotepa University of California, San Francisco | Phase 2 | BB |
Fludarabine Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | BB |
HUMAN IMMUNOGLOBULINS Grifols Therapeutics LLC | Phase 3 | B |
View all 23 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →